Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 9 VictozaⓇ maintains leadership in the faster growing US GLP-1 market US GLP-1 market development MAT Total TRX GLP-1 TRx (million) MAT volume US GLP-1 market TRx volume GLP-1 TRX - VictozaⓇ volume - albiglutide - US GLP-1 market shares VictozaⓇ albiglutide exenatide dulaglutide 8 7 6 5 4 1 32 O 0 Aug 2013 exenatide GLP-1 TRX Growth rate growth rate dulaglutide market - (million) share 35% 0.40 100% 30% 80% 0.30 25% - 20% 60% 51% 0.20 15% 40% 22% - 10% 19% 0.10 20% 5% 8% 0% 0.00 0% Aug Aug Aug Aug Aug 2016 2013 2016 2013 2016 Source: IMS NPA monthly, August 2016 changing diabetes® novo nordisk

View entire presentation